The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.
October 30th 2024
A decade after bariatric surgery, most teens maintained weight loss and reduced obesity-related conditions such as type 2 diabetes and hypertension.
HCPLive Endocrinology's flagship diabetes podcast, hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP
Diabetes Dialogue: What Teplizumab Means for Type 1 Diabetes
November 17th 2022In this special edition episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, break down what the approval of teplizumab means for type 1 diabetes. During the episode, hosts take a deep dive into type 1 diabetes staging and hypothesize around the role of CDCES in educating primary care and other specialties to optimize the potential of teplizumab.
FDA Issues Recall for Insulet Devices for Battery, Overheating Issues that Could Cause Fire
November 17th 2022Announced on November 17, the US FDA Class I recall for the Insulet Omnipod DASH Insulin Management System Personal Diabetes Manager comes after the company had received more than 450 complaints related to battery swelling, fluid leakage from battery, and extreme overheating, including 3 instances that included fires.
Diabetes Dialogue: Obesity Updates, with Lydia Alexander, MD
November 14th 2022In this episode, our hosts are joined by Lydia Alexander, MD, president-elect of the Obesity Medicine Association, to discuss the updates in the landscape of obesity management as well as a deep dive into the recent American Gastroenterological Association guidelines for pharmacological management and the OMA's annual meeting.
Role of Obesity Management in Cardiovascular Disease Prevention, with Diana Isaacs, PharmD
November 9th 2022At AHA 2022, Diana Isaacs, PharmD, provides perspective on the potential impact of optimized uptake of newer obesity medications could have on population-level cardiovascular disease prevention.
STEP TEENS: Semaglutide 2.4 mg (Wegovy) Weight Loss Benefits Translate to Adolescent Populations
November 2nd 2022Data from the STEP TEENS trial, which assessed the benefits of semaglutide 2.4 mg (Wegovy) in individuals aged 12-18 years with overweight or obesity, indicates use of the GLP-1 receptor agonist was associated with a mean reduction in body weight of 16% during the 68-week trial.
Endocrine Month in Review: October 2022
October 29th 2022The October 2022 month in review recap includes a pair of studies that paint a grim picture related to the burden of diabetes in the US, a trio of new obesity guidelines/reports from major national and international organizations, and news related to the latest developments in the world of continuous glucose monitoring.
Increased Scanning Frequency Improves Glucose Control, Hypoglycemia Fear in T1D Using CGM
October 28th 2022An analysis of patient data from people with type 1 diabetes using flash glucose monitoring suggests increased scanning frequency could improve glycemic control and reduce fear of hypoglycemia in people using intermittently scanned continuous glucose monitoring.
Diabetes Dialogue: GLP-1 RA Shortage & ADA/KDIGO Recommendations
October 24th 2022In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the ongoing GLP-1 RA shortage and whether or not celebrities using these agents for weight loss is a real issue in the community as well as provide insight into their top takeaways from the ADA/KDIGO consensus report.
American, International Organizations Debut New Bariatric and Metabolic Surgery Guidelines
October 23rd 2022Published on October 21, the metabolic and bariatric surgery guideline considerations from the American Society of Metabolic and Bariatric Surgery and the International Federation for the Surgery of Obesity and Metabolic Disorders represent the first major updates to guidance since a National Institutes of Health document released in 1991.
American Gastroenterological Association Releases Guidelines for Pharmacologic Management of Obesity
October 20th 2022Released on October 20, the American Gastroenterological Association's guidelines for obesity management with pharmacological therapy endorses semaglutide 2.4 mg (Wegovy), phentermine-topiramate ER (Qsymia), lirgalutide 3 mg (Saxenda), and naltrexone-bupropion ER (Contrave) as first-line medical therapies in addition to diet and exercise for weight loss in people with obesity.
Diabetes Dialogue: EASD 2022 and CGM News
October 13th 2022In this special edition episode of Diabetes Dialogue, our hosts break down their top clinical takeaways from the European Association for the Study of Diabetes 2022 annual meeting, new data from the FLASH-UK trial, the global launch of Dexcom G7, and the announcement of US availability for the FreeStyle Libre 3.
Flash Glucose Monitoring Can Improve Glycemic Control, Time in Range in Type 1 Diabetes
October 10th 2022Data from the FLASH-UK trial, which compared FreeStyle Libre 2 against usual care for glycemic control in type 1 diabetes, provide evidence demonstrating improved glycemic control and time in target glucose range among users of the FreeStyle Libre 2 system.
American Diabetes Association, EASD Publish Joint Consensus Report on Automated Insulin Delivery
October 7th 2022Released on October 6, the joint consensus report from the ADA and EASD provides an overview of the benefits and safety concerns related to AID systems as well as offering a multitude of evidence-based recommendations on the subject.
The Endocrine Society Releases New Guidance for Telehealth Use
October 5th 2022On October 4, the Endocrine Society announced the release of a 10-page policy perspective outlining guidance related to optimal use of telehealth in endocrine care, which was composed by a 9-member panel led by Varsha G. Vimalananda, MD, MPH.